About iO BiO Sciences
iO BiO Sciences developed a novel, proprietary, genetic cell modification technology (GEMS™), allowing efficient, plug-and-play, manufacturing of Advanced Therapy Medicinal Products and Biomolecule Manufacturing.
The GEMS™ technology is used to develop clinical off-the-shelf cell therapies in oncology using a universal NK cell derived from a proprietary pluripotent stem cell.
iO BiO Sciences technology is also applicable to biomanufacturing of proteins or viral vectors in stable mammalian cell lines converting producer cell lines into a plug-and-play manufacturing systems with only one variable: the gene of interest.
Enable the rapid development of cell therapies to fight cancer using off-the-shelf natural killer cells derived from a unique stem source and engineered for flexibility, efficacy, and mass production.
iO BiO is focused on developing Natural Killer Cell therapies to fight cancers, initially focused on liver cancer. Our multi-part system allows for flexible therapy development and license opportunities.
CAR-NK-based Cell Therapy
Immune Cell Therapies Engineered for Efficacy and Mass Production
Sicco H Popma, PhD
CEO & President iO Biosciences, Inc
25+ Years Research & Development Experience
13 Years Johnson & Johnson
15+ Years Cell Therapy Development
PhD, Immunology, Univ. Groningen, The Netherlands
Scientist. U. Pennsylvania, USA
President ZMI Electronics
10+ Years Cell Therapy Development, Accelerated Biosciences.
EMBA CEIBS, Shanghai, China
BA UC Berkeley, Economy & Law, USA
CEO C14 Consulting
25+ Years business development, marketing and entrepreneurial experience in biotherapeutics, immunotherapies and regenerative medicine.
BS, Chemistry Drexel University
iO BiO Sciences Investors
Contact Sicco Popma for investment opportunities